UCB - Net Income


UCB reported EUR1.08B in Net Income for its fiscal semester ending in December of 2025.





Net Income Change Date
Alcon AG USD 189M 28M Mar/2026
Almirall EUR 19.58M 7M Dec/2025
Amarin USD -1.22M 6.51M Dec/2025
argenx SE USD 506M 34M Sep/2026
AstraZeneca USD 2.51B 573M Jun/2026
Bayer EUR 219M 2.54B Jun/2026
Genmab DKK 303M 250M Jun/2026
GlaxoSmithKline GBP 1.54B 1.11B Sep/2026
GRIFOLS EUR 154M 81M Jun/2026
Hikma Pharmaceutical USD 164M 45M Dec/2025
Lakefront Biotherapeutics EUR 2.11M 12.38M Jun/2026
Lonza CHF 426M 119M Jun/2025
Merck EUR 490M 169M Jun/2026
Novartis USD 3.26B 108M Jun/2026
Orion EUR 167.6M 27.4M Sep/2026
Recordati EUR 116.61M 36.45M Jun/2026
Roche Holding CHF 6.87B 1.4B Jun/2026
Sanofi EUR 343M 1.27B Jun/2026
UCB EUR 1.08B 608M Dec/2025
Unibail Rodamco EUR 532.1M 123.6M Dec/2025